Topoisomerase (DNA) II beta 180kDa (TOP2B) (AA 1281-1494) antibody
| Antigen | Topoisomerase (DNA) II beta 180kDa (TOP2B) |
| Synonyms | TOPIIB, top2beta, TOP2B |
| Binding Site |
Alternatives AA 1281-1494 |
| Clonality | Monoclonal (40) |
| Host |
Alternatives Mouse |
| Reactivity |
Alternatives Human |
| Application |
Alternatives BioImaging (BI), Western Blotting (WB), Immunofluorescence (IF) |
![]() |
5 references available |
| Catalog no. | ABIN968561 |
| Quantity |
|
| Price | Product not available in this region. |
| Shipping to |
|
Additional Information
| Alternative name | Topo II beta |
| Immunogen | Human Topo IIbeta |
| Format | Liquid |
| Isotype | IgG1 |
| Clone | 40 |
| Description | Eukaryotic DNA topoisomerase II, a ubiquitous ATP-dependent type II topoisomerase, is an essential nuclear enzyme in DNA replication and transcription, chromatin segregation, and cell cycle progression. Topoisomerases transiently break a pair of complementary strands in double-stranded DNA to form a gate for the passage of duplex DNA. Two isoforms of DNA topoisomerase II have been identified: topo IIalpha and topo IIß. These exhibit a high degree of homology, except for some divergence in the C-terminal region. Both contain multiple bipartite nuclear localization sequences (NLS) that mediate their subnuclear localization. Topo IIalpha levels rise during late S phase and peak in G2-M, whereas topo IIß levels remain constant throughout the cell cycle. In addition, topo IIalpha is expressed in proliferating cells, while topo IIß is expressed in a wide range of tissues. Although the exact role of these two isoforms during cell proliferation is not known, the differences in cellular expression implicate different physiological roles. Both isoforms may also be important targets for anticancer agents that exert cytotoxicity in proliferating cells via stabilization of a topo II-DNA complex. This antibody is routinely tested by Western blot analysis and immunofluorescent imaging. |
| Characteristics |
1. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. 2. Since applications vary, each investigator should titrate the reagent to obtain optimal results. 3. Source of all serum proteins is from USDA inspected abattoirs located in the United States. 4. Please refer to us for technical protocols. |
| Molecular Weight | 180 kDa |
| Comments |
Related Products: ABIN968537, ABIN967389 |
Application Details
| Application Notes |
Methanol Procedure for a 96 well plate: Remove media from wells. Add 100 µl/well fresh 3.7% Formaldehyde in PBS. Incubate for 10 minutes at room temperature (RT). Flick out and add 100 µl/well 90% methanol. Incubate for 5 minutes at RT. Flick out and wash twice with PBS. Flick out PBS and add 100 µl/well blocking buffer (3% FBS in PBS). Incubate for 30 minutes at RT. Flick out and add diluted antibody (diluted in blocking buffer). Incubate for 1 hour at RT. Wash three times with PBS. Flick out PBS and add second step reagent. Incubate for 1 hour at RT. Wash three times with PBS. Triton-X 100 Procedure for a 96 well plate: Remove media from wells. Add 100 µl/well fresh 3.7% Formaldehyde in PBS. Incubate for 10 minutes at room temperature (RT). Flick out and add 100 µl/well 0.1% Triton-X 100. Incubate for 5 minutes at RT. Flick out and wash twice with PBS. Flick out PBS and add 100 µl/well blocking buffer (3% FBS in PBS). Incubate for 30 minutes at RT. Flick out and add diluted antibody (diluted in blocking buffer). Incubate for 1 hour at RT. Flick out and wash three times with PBS. Flick out and add second step reagent. Incubate for 1 hour at RT. Flick out and wash three times with PBS. |
| Concentration | 250 µg/ml |
| Purity | Purified |
| Purification | Purified from tissue culture supernatant or ascites by affinity chromatography. |
| Buffer | Aqueous buffered solution containing BSA, glycerol. |
| Preservative | 0.09% Sodium azide. |
| Storage | Store undiluted at -20° C. |
| Restrictions | For Research Use only |
Images
Publications
| Product |
Tsai-Pflugfelder, Liu, Liu et al.: "Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 85, Issue 19, pp. 7177-81, 1988 (PubMed).
Brown, Holden, Rahn et al.: "Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease." in: American journal of clinical pathology, Vol. 109, Issue 1, pp. 39-44, 1998 (PubMed). Herzog, Holmes, Tuschong et al.: "Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha." in: Cancer research, Vol. 58, Issue 23, pp. 5298-300, 1998 (PubMed). Suzuki, Tomida, Tsuruo: "Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia." in: Oncogene, Vol. 20, Issue 41, pp. 5779-88, 2001 (PubMed). Shain, Landowski, Dalton: "Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 168, Issue 5, pp. 2544-53, 2002 (PubMed). |
Alternatives
Alternatives for antigen "Topoisomerase (DNA) II beta 180kDa (TOP2B)", type "Antibodies"
| Hosts | Rabbit (32) |
| Reactivities | Human (30), Mouse (Murine) (7), Rat (Rattus) (2) |
| Applications | Western Blotting (WB) (20), ELISA (12), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (9), Immunohistochemistry (IHC) (7), Immunofluorescence (IF) (3), Immunocytochemistry (ICC) (1), Immunoprecipitation (IP) (1) |
| Epitopes | C-Term (6), Internal Region (2), AA 1475-1525 (1), N-Term (1) |




Alternatives